Announcements Trials
Browse Landscape

Phase

Phase 2 195Phase 3 66Phase 1 37Phase 1/2 26Phase NA 5Phase 4 5Phase 2/3 5

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 7Breast Neoplasms 6Lung Neoplasms 5Ovarian Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Neoplasms 2Medulloblastoma 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Thymic epithelial tumor 1Thrombocythemia, Essential 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Squamous NSCLC 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1Primary Malignant Neoplasm of Ovary 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 5pembrolizumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Docetaxel 4Gemcitabine 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cemiplimab 2auricularum 2Specimen Handling 2Ramucirumab 2Radiotherapy 2Leucovorin 2Erlotinib Hydrochloride 2Drug Therapy 2Calcium Dobesilate 2pertuzumab 1oblimersen 1maimendongtang 1endostar protein 1cyclopropapyrroloindole 1cediranib 1aumolertinib 1anamorelin 1Vitamin B 12 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Carboplatin × Clear all
NCT07100080 2026-05-27

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Bristol-Myers Squibb

Phase 2/3 Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07063745 2026-05-18

MountainTAP-29

Bristol-Myers Squibb

Phase 2/3 Recruiting
590 enrolled
Thoracic

Lung Neoplasms

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Regeneron Pharmaceuticals

Phase 2/3 Active not recruiting
950 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00245154 2023-08-04

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Canadian Cancer Trials Group

Phase 2/3 Completed
296 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00006229 2020-04-06

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Canadian Cancer Trials Group

Phase 2/3 Completed
774 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡